JOSE PERAL GUTIERREZ DE CEBALLOS

Dr. JOSE PERAL GUTIERREZ DE CEBALLOS

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JCJOSE PERAL GUTIERREZ DE CEBALLOS
JOSE PERAL GUTIERREZ DE CEBALLOS
ÁEÁngel Estella
Ángel Estella
XNXavier Nuvials
Xavier Nuvials
ALEJANDRO HUGO RODRIGUEZ OVIEDOALEJANDRO HUGO RODRIGUEZ OVIEDO
ALEJANDRO HUGO RODRIGUEZ OVIEDO
ISIratxe Seijas
Iratxe Seijas
RZRafael Zaragoza
Rafael Zaragoza
The aim of this study was to establish practical recommendations for the diagnosis and treatment of influenza-associated invasive aspergillosis (IAPA) based on the available evidence and experience acquired in the management of patients with COVID-19-associated pulmonary aspergillosis (CAPA). The CAPA/IAPA expert group defined 14 areas in which recommendations would be made. To search for evidence, the PICO strategy was used for both CAPA and IAPA in PubMed, using MeSH terms in combination with free text. Based on the results, each expert developed recommendations for two to three areas that they presented to the rest of the group in various meetings in order to reach consensus. As results, the practical recommendations for the management of CAPA/IAPA patients have been grouped into 12 sections. These recommendations are presented for both entities in the following situations: when to suspect fungal infection; what diagnostic methods are useful to diagnose these two entities; what treatment is recommended; what to do in case of resistance; drug interactions or determination of antifungal levels; how to monitor treatment effectiveness; what action to take in the event of treatment failure; the implications of concomitant corticosteroid administration; indications for the combined use of antifungals; when to withdraw treatment; what to do in case of positive cultures for Aspergillus spp. in a patient with severe viral pneumonia or Aspergillus colonization; and how to position antifungal prophylaxis in these patients. Available evidence to support the practical management of CAPA/IAPA patients is very scarce. Accumulated experience acquired in the management of CAPA patients can be very useful for the management of IAPA patients. The expert group presents eminently practical recommendations for the management of CAPA/IAPA patients.

23 June 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
BSBorja Suberviola
Borja Suberviola
JCJOSE PERAL GUTIERREZ DE CEBALLOS
JOSE PERAL GUTIERREZ DE CEBALLOS
MMMaria Jose Asensio Martin
Maria Jose Asensio Martin
MSMaria Cruz Soriano
Maria Cruz Soriano
RZRafael Zaragoza
Rafael Zaragoza
MSMiguel Santibáñez
Miguel Santibáñez
Purpose: This study aims to determine the incidence of kidney injury associated with liposomal amphotericin B (L-AmB) treatment, based on RIFLE criteria, in patients admitted to the intensive care unit (ICU) with invasive pulmonary aspergillosis (IPA). Materials and Methods: A retrospective, multicenter observational study including patients treated with L-AmB for IPA while admitted to the ICU between 1 January 2015, and 31 December 2022. Results: A total of 65 patients were included. The prevalence of renal failure was 35.39%. Renal failure was mostly mild and reversible. The need for major surgery (OR 6.71; p = 0.121) and concomitant use of other nephrotoxic treatments (OR 2.5; p = 0.194) emerged as potential risk factors for the development of renal failure; however, neither association reached statistical significance. Overall mortality was 66.2%, significantly higher in the group with renal failure (82.6% vs. 57.1%; p = 0.03). Factors associated with mortality included concomitant use of other nephrotoxic agents (OR 4.51; p = 0.024) and development of renal failure (OR 3.66; p = 0.068). Duration of L-AmB treatment was not associated with mortality. Regarding creatinine recovery, all patients who developed renal failure but survived showed creatinine levels below 1.5 mg/dL after completion of treatment. Conclusions: Renal impairment was common in this high-risk population of critically ill patients, with renal function impairment in one-third of exposed patients, although most cases were mild. In this population, concomitant administration of other nephrotoxic drugs was associated with both renal failure and mortality. Treatment duration with L-AmB was not linked to mortality, and creatinine levels normalized after therapy completion.